Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States
Even after release of the ACGD guidelines, adjuvant BMA prescribing was low, and the majority of patients who received BMA did not receive bisphosphonates.
Authors
- Julia Foldi (ORCID: https://orcid.org/0000-0002-7504-867X)
- Rachel Jaber Chehayeb (ORCID: https://orcid.org/0000-0002-2117-7433)
- Nicole Odzer
- Cary P. Gross (ORCID: https://orcid.org/0000-0002-4974-935X)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- Sarah Schellhorn (ORCID: https://orcid.org/0000-0002-8837-1425)
- Do Kyeong Lee (ORCID: https://orcid.org/0000-0003-4295-872X)
Institutions
- Hospital of the University of Pennsylvania (US)
- Yale Cancer Center (US)
- UPMC Health System (US)
- UPMC Hillman Cancer Center (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1186/s13058-025-02062-1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences